Dr. Jason Vassy
@jasonvassy
Followers
7K
Following
814
Media
103
Statuses
699
Primary care physician and genomic medicine researcher @VABostonHC | Assoc Prof @HarvardMed | @BrighamWomens | @Genomes2People
Boston, MA
Joined December 2007
Get a taste of the ASHG community before fall! Join us for the virtual Spring Symposium on Cancer Genetics Symposium on April 8-9! It’s a great way to connect before the meeting in Boston, plus you can earn up to 6 CME credits. Register now: https://t.co/HkQK1pVcG5
#ASHG
0
1
8
Can a clinical polygenic model improve prostate cancer screening? We now describe our P-CARE model and its application in the new ProGRESS clinical trial: From a genomic risk model to clinical trial implementation in a learning health system: https://t.co/wnomij3leS
0
5
38
I’m excited to bring @DeptVetAffairs and @VeteransHealth to this network of other genomics-enabled learning health systems! We will promote the uptake of evidence-based genomic medicine in patient care. https://t.co/Atpwp2C1J9
2
1
26
Health-literate care organizations use system-wide approaches to help all patients understand and engage in their own care. @marlaclayman, Maren Scheuner, and I propose applying these ideas to precision health. https://t.co/JA1PzhQ0Su
What is a health-literate health care organization and how can this be applied to precision healthcare to achieve #HealthEquity? https://t.co/cimifcgULY
#PrecisionMedicine
0
0
7
Excited to have brought MCED testing to Veterans at VA Boston!
Galleri is a new type of cancer screening that can detected 50+ different types of cancer with a simple blood draw. Veterans seen at VABHS are eligible for Galleri testing as part of The REFLECTION Study. Contact Charlene.Preys@va.gov or 617-777-9441 to learn more.
0
0
5
Join us today at 12pm ET!
THIS WEDNESDAY, our live web event will dive into four real-world solutions: ➡️Hub-and-spoke ➡️Train-the-PCP ➡️PCP extender ➡️Specialty integration models Learn how to implement these strategies in your practice as a #GeneticsSpecialist; register now: https://t.co/PTH2PLKVmU
0
0
4
Today at 12pm ET: Join me and stellar colleagues as we discuss the role of primary care in expanding access to genetics services. "Novel delivery models to meet the demand for genetics services in primary care" @GeneticsSociety
https://t.co/zt2HFgso0z
0
0
8
And we’re doing our part for evidence generation, too. Watch this space for our progress on ProGRESS, an RCT of genomics-informed screening:
0
1
5
In the meantime, it was very rewarding to help @PCFnews develop screening recommendations specifically for Black men, who have 2x the risk of prostate cancer mortality. Led by @WilliamOhMD and now out in @NEJMEvidence: https://t.co/sXHL3OBuZC
evidence.nejm.org
In the United States, Black men are at highest risk for being diagnosed with and dying from prostate cancer. Given this disparity, we examined relevant data to establish clinical prostate-specific ...
1
1
7
It will be interesting to see whether/how family history, race/ethnicity, and novel biomarkers including genomics are incorporated into the new guidelines.
1
1
2
You might be aware that the USPSTF is currently updating their 2018 guidelines, which recommended shared decision-making for men 55-69 (Grade C recommendation). Draft research plan for the updated guidelines here:
1
1
2
There is a lot of movement in prostate cancer screening research and practice these days, as this week’s @JAMA_current illustrates: 🔵 15-year update to CAP trial 🔵 Preliminary communication from ProScreen 🔵 Insightful editorial by @UroOncJT and colleagues 1/n
Prostate Cancer Screening, Clinical Outcomes for Cancer Drugs Granted Accelerated Approval, Lupus Review, and more. JAMA Associate Editor Anne Rentoumis Cappola summarizes the May 7 issue. Hosted on @amaedhub.
2
3
10
Excited to be going “home” to @WUSTLmed this morning to speak about #PGx research and clinical care in the @VeteransHealth Administration.
0
0
5
Fascinating use of cancer PRS for causal estimation of the cost-effectiveness of preventive interventions.
New paper: estimating long-term intervention cost-effectiveness in the absence of data from RCTs and without recourse to Markov models or similar. Methods demonstrated with repurposed use of SGLT2 inhibitors to reduce risk of incident prostate cancer
0
2
4
It’s great to share the impressive PCP-genetics e-consult initiative Ben Kerman has led at @BrighamWomens for the last 5 years.
Can an electronic consultation service led by a "primary care physician champion" triage and respond to genetics questions? The answer is yes, and it yields high provider satisfaction https://t.co/9tspHrEphI
@jasonvassy #GIMO #ReferralAndConsultation #Genetics #PrimaryHealthcare
0
0
2
VA healthcare now expanding to an unprecedented number of Veterans! @VeteransHealth
0
2
5
Testing ALL women aged 30 to 35 years for BRCA1, BRCA2, and PALB2 was cost-effective in this modeling study, compared with family history-based approach https://t.co/Ym2w9FkdUj
jamanetwork.com
This economic evaluation examines the cost-effectiveness of population-based multigene testing compared with family history–based testing in simulated patients with breast and ovarian cancer.
0
2
8
Congrats to the eMERGE team! Detailed look at a PRS implementation pipeline, including a discussion of the diseases that weren’t yet ready for prime time. https://t.co/eEOBRbCrs8
0
2
11
And now testing the clinical implementation of those discoveries:
VA’s largest research program is making discoveries to help improve health care for Black Veterans. https://t.co/4LH7i972ac
0
0
4
Perspective: "A Tale of Two Scores: Comparing Coronary Artery Calcium and Polygenic Risk Scores for the Prediction of Coronary #Heart Disease Events" by @jasonvassy & @marstonMD
#MedTwitter #PathTwitter #MedX #LabMedX 👉 https://t.co/wkZawGmZJQ
0
4
8